Unsuccessful and disappointing clinical trials for AstraZeneca’s lung cancer drug

Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.

AstraZeneca today announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC).

Click on this link for more information.